YOLFTbeta
68

Hangzhou Alltest Biotech Co. Ltd. A

688606 · SHG · Healthcare / Medical Instruments & Supplies

44.34CNY-0.91 (-2.01%)

Price History

Full chart

Market Stats

Previous Close45.25
Open45.30
Day Range44.09 – 45.83
52-Week Range39.80 – 71.34
Volume300.47K
Market Cap3.77B
P/E (TTM)28.46
Forward P/E0.00
EPS1.75
Dividend Yield4.02%
Beta0.17
50-Day Avg46.26
200-Day Avg55.29

About

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers COVID-19 solutions, such as antigen combo rapid and antigen test range; HUMAN RAPID TESTs, including women's health, infectious disease, drugs of abuse, tumor markers, cardiac markers, home use, and other rapid tests; LF readers; and veterinary products comprising veterinary chemiluminescence and fluorescence immunoassay, veterinary LF readers, dry biochemistry, and immunoblotting, as well as canine, feline, porcine, and bovine test ranges. It also provides fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, blood glucose monitoring systems; Hb hemoglobin test meters, cholesterol meters, and VTM products; PCR kits; immunoblotting test kits; chemiluminescence immunoassay analyzers and tests; and blood grouping reagents. Hangzhou Alltest Biotech Co., Ltd. was founded in 2009 and is headquartered in Hangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Fei Gao
  • Employees960
  • HeadquartersBuilding 3, 4, 5, Hangzhou, China, 310018, China
  • Websitehttps://www.alltests.com.cn

Leadership

  • Mr. Fei GaoChairman & GM · b. 1974
  • Ms. Yanping FuAccounting Supervisor, CFO & Secretary of the Board of Directors · b. 1978
  • Mr. Weike LuDeputy GM & Director · b. 1981

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue75.70M129.72M184.19M241.34M1.14B1.87B3.39B754.70M866.58M911.30M
Growth (%)-+71.36%+41.99%+31.03%+370.53%+64.98%+80.88%-77.73%+14.83%+5.16%
Cost of Revenue31.04M47.94M70.44M88.64M204.18M843.87M1.56B380.66M392.82M444.09M
Gross Profit44.66M81.78M113.75M152.70M931.37M1.03B1.83B374.04M473.77M911.30M
Gross Margin58.99%63.05%61.75%63.27%82.02%54.96%53.87%49.56%54.67%100.00%
Operating Expense27.19M44.01M51.21M64.59M138.65M132.81M431.68M162.46M128.25M661.55M
Operating Income17.46M37.77M62.53M88.11M792.73M896.75M1.39B211.58M345.52M249.75M
Operating Margin23.07%29.12%33.95%36.51%69.81%47.87%41.13%28.04%39.87%27.41%
EBITDA18.63M39.73M65.32M91.67M796.55M906.24M1.41B221.49M375.44M274.95M
EBITDA Margin24.61%30.62%35.46%37.98%70.15%48.37%41.56%29.35%43.32%30.17%
Net Income15.21M34.17M56.43M78.42M679.23M765.69M1.18B180.58M302.47M218.28M
Net Income Margin20.09%26.34%30.63%32.49%59.81%40.87%34.97%23.93%34.90%23.95%
R&D20.12M25.94M30.94M35.93M55.11M95.46M207.30M121.17M95.82M109.32M
R&D as % of Total Revenue26.58%20.00%16.80%14.89%4.85%5.10%6.12%16.06%11.06%12.00%
Interest Expense-422.00K436.20K604.00K844.82K1.93M3.70M2.89M1.89M280.38K
Interest Expense % of Total Revenue-0.33%0.24%0.25%0.07%0.10%0.11%0.38%0.22%0.03%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets59.73M190.58M254.56M332.50M1.15B4.01B4.70B4.12B4.19B4.24B
Total Liabilities32.42M51.97M39.47M39.30M178.45M734.71M528.80M284.50M302.60M296.09M
Total Equity27.16M138.61M215.10M293.20M972.66M3.27B4.17B3.83B3.88B3.95B
Cash7.91M43.26M11.94M63.25M285.64M2.18B1.98B1.32B920.38M1.07B
Total Debt----4.43M37.36M21.77M23.91M1.76M-
Net Debt-7.91M-43.26M-11.94M-63.25M-281.21M-2.14B-1.96B-1.29B-918.62M-

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow6.72M19.99M18.60M91.53M622.72M923.87M1.36B24.76M329.52M206.59M
Investing Cash Flow-2.08M-52.12M-69.63M-40.39M-384.92M-531.35M-1.26B-140.67M-479.06M-
Financing Cash Flow573.19K67.85M19.35M--6.75M1.52B-361.91M-558.99M-272.73M-
Capital Expenditure2.08M52.12M34.66M15.09M37.11M140.12M270.24M533.49M220.65M219.10M
Free Cash Flow4.63M-32.12M-16.06M76.44M585.61M783.75M1.09B-508.73M108.87M-12.50M
Dividends Paid-----107.81M215.62M528.68M232.66M195.11M
FCF to OCF68.97%-160.68%-86.34%83.52%94.04%84.83%80.14%-2054.33%33.04%-6.05%
Dividend Paid to FCF-----13.76%19.77%-103.92%213.71%-1560.40%

Earnings

Report DateMar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Sep 5, 2022Oct 29, 2022Dec 31, 2022Apr 28, 2023
EPS Estimate---------
EPS Actual1.882.201.963.5513.154.701.09-2.250.77
Surprise---------
Timing-----After-hoursAfter-hours-After-hours

Key Statistics & Ratios

Market Cap3.77B
Enterprise Value1.48B
Trailing P/E28.46
Forward P/E0.00
Price / Sales4.34
Price / Book0.96
EPS1.75
Book Value49.61
Revenue (TTM)867.64M
Gross Profit (TTM)421.86M
EBITDA168.04M
Profit Margin16.02%
Operating Margin16.88%
Return on Equity3.62%
Return on Assets1.87%
Shares Outstanding75.65M
Shares Float25.73M
Beta0.17
Dividend Yield4.02%
Dividend Rate2.00
Payout Ratio114.29%

Dividends

20261×
1.00Jun 1, 2026
20252×
1.00Oct 16, 20251.50Jun 11, 2025
20242×
1.50Oct 25, 20241.50Jun 20, 2024
20231×
6.76Jun 9, 2023
20221×
2.70Jun 7, 2022
20211×
1.35Jun 10, 2021

Stock Splits

  • Jun 9, 20231.48:1